A 2-year study comparing the efficacy and safety of anti-VEGF drugs (aflibercept and brolucizumab) in patients with exudative age-related macular degeneration.
Latest Information Update: 30 Sep 2020
At a glance
- Drugs Aflibercept (Primary) ; Brolucizumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- 28 Sep 2020 Planned number of patients changed from 100 to 140.
- 14 Aug 2020 New trial record